BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
World's top technology exhibition CES 2021
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Industry > article

New drug for neutropenia seeks FDA sanction

Park Sae-jin Reporter(swatchsjp@ajunews.com) | Posted : December 28, 2018, 16:05 | Updated : December 28, 2018, 16:05
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Hanmi Pharmaceutical]



SEOUL -- The American partner of South Korea's leading drug maker Hanmi Pharmaceutical has applied for approval to sell Rolontis, a new biologic medicine for neutropenia, an abnormally low level of white blood cells.

Hanmi said Friday that Spectrum Pharmaceuticals has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for Rolontis, which used Hanmi's technology called "Long Acting Protein/Peptide Discovery (Lapscovery)."

Lapscovery is a platform technology that prolongs the duration of action of biologics, making it possible for patients to take weekly or monthly medication or injection instead of taking them daily. Spectrum imported Lapscovery in 2012 to produce Rolontis.

Neutropenia is an abnormally decreased number of neutrophils in leukocytes due to chemotherapy or infection. Neutrophils play an important role in immunity. Spectrum found Rolontis was found to be effective and safe in clinical tests on 643 patients with early-stage breast cancer who showed an abnormally low level of neutrophils.

  • Park Sae-jin Reporter
  • email : swatchsjp@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Hanmis cancer therapy Oraxol gets FDAs special designation.
    Hanmi's cancer therapy Oraxol gets FDA's special designation
  • .Hanmi partners with American biotech company to develop multiple bispecific antibodies..
    Hanmi partners with American biotech company to develop mult…
  • .Hamis anti-obesity drug approved by FDA for rare pediatric disease program.
    Hami's anti-obesity drug approved by FDA for rare pediatric …
  • .Hanmi Pharmaceuticals HM43239 anti-cancer drug wins FDA designation.
    Hanmi Pharmaceutical's HM43239 anti-cancer drug wins FDA des…
  • .Hanmi partners with RAPT Therapeutics to develop and commercialize FLX475 for cancer treatment.
    Hanmi partners with RAPT Therapeutics to develop and commerc…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • Singer IU drops teaser image for upcoming full album
  • Hyundai to complete construction of fuel cell production plant in China in 2022
  • Seoul builds solar power plant on idle land near urban expressway
  • Samsung showcases new Galaxy S21 smartphone models
  • Southern city launches joint research project to develop heavy-duty flying taxi drone
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view